Century Therapeutics
Develops iPSC-derived allogeneic cell therapies for autoimmune disease and cancer.
Something off on this page? Send us feedback.
Profile
Develops off-the-shelf, iPSC-derived cell therapies for autoimmune disease, including type 1 diabetes, and cancer. Its development pipeline includes beta-islet, alpha-beta immune T-cell, and CAR-iNK programs.
Develops off-the-shelf, iPSC-derived allogeneic cell therapies for autoimmune disease, including type 1 diabetes, and cancer. The platform combines induced pluripotent stem cells with gene editing, protein engineering, technical development, and manufacturing.
Current programs include CNTY-813, a beta-islet-cell program for type 1 diabetes; CNTY-308, a CD19-targeted alpha-beta immune T-cell program for B-cell-mediated autoimmune diseases; and CNTY-101, a CD19 CAR-iNK program in an investigator-sponsored trial. These are development programs, not approved commercial products.
Operates as a research-and-development biotechnology business with one reportable segment. The business depends on clinical progress, manufacturing, licensing and collaboration arrangements, and financing.
Company facts
Key statistics
Year to date +105% · Average volume (30d) 561.0K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Mar 13, 2026 | Leerink Partners | Target | $27 | $2 | ||
| Jan 20, 2026 | Piper Sandler | Reiterate | Overweight | $9 | $4 | |
| Nov 17, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.11 | −$0.17 | −54.5% | $2.2M | — | — | −1.53% |
| Aug 12, 2026Q2 FY26 | −$0.11 | −$0.17 | −54.5% | $2.2M | — | — | −4.85% |
| May 13, 2026Q1 FY26 | −$0.15 | −$0.11 | +26.7% | $2.9M | — | — | +4.39% |
| Mar 12, 2026Q4 FY25 | −$0.28 | −$0.25 | +10.7% | −$62.5K | — | — | −6.40% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $109.2M | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $109.2M | −$26.9M | −$22.5M | $0 | −$3.0M | $0 | |
| Operating income | $74.2M | −$34.7M | −$36.1M | −$20.7M | −$25.5M | −$36.5M | |
| Net income | $76.6M | −$32.5M | −$34.4M | −$19.2M | −$21.6M | −$34.6M | |
| Diluted EPS | $0.89 | −$0.38 | −$0.40 | −$0.22 | −$0.25 | −$0.17 | |
| Gross margin | 100.0% | — | — | — | — | — | |
| Operating margin | 67.9% | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $5.2M · FY23 $2.2M · FY24 $6.6M · FY25 $109.2M
Balance sheet, Jun 30, 2026Cash & short-term investments $119.7M · Total debt $34.6M · Total assets $287.0M · Shareholders' equity $232.3M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 86.57M · Float 48.65M · 56.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 17.75M | 20.51% | 13F | May 15, 2026 |
| TCG Crossover Management, LLC | 17.75M | 20.51% | 13F | May 15, 2026 |
| RTW Investments, LP | 13.04M | 7.10% | 13G | May 15, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 13.04M | 7.10% | 13G | Jan 16, 2026 |
| Versant Venture Management, LLC | 12.17M | 14.05% | 13F | May 5, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Douglas Carr | officer: SVP Finance & Operations | −275 | $1.98 |
| Jun 12, 2026 | Douglas Carr | officer: SVP Finance & Operations | −1,654 | $2.23 |
| Jun 12, 2026 | Gregory Russotti | officer: See Remarks | −2,584 | $2.23 |
| Jun 8, 2026 | Douglas Carr | officer: SVP Finance & Operations | −249 | $2.11 |
| Jun 8, 2026 | Gregory Russotti | officer: See Remarks | −524 | $2.11 |
Peers
- Vertex Pharmaceuticals
Stem-cell-derived islet replacement for type 1 diabetes
- Sana Biotechnology
Hypoimmune iPSC-derived islet therapy for type 1 diabetes
- CRISPR Therapeutics
Gene-edited allogeneic cell programs in diabetes and autoimmunity
- Allogene Therapeutics
Dual-targeted allogeneic CAR-T for B-cell autoimmune disease
- Fate
iPSC-derived off-the-shelf CD19 CAR-T and CAR-NK programs
- Nkarta
Allogeneic CD19 CAR-NK therapy for B-cell autoimmune diseases
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Century Therapeutics | $2.03 | +0.25% | $175.3M | — | — | — | — |
| Vertex Pharmaceuticals | $540.78 | −0.17% | $137.48B | 31.5 | 27.8 | 10.9 | +12.5% |
| Sana Biotechnology | $3.95 | +0.51% | $1.09B | — | — | — | — |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Fate | $2.43 | +0.60% | $283.2M | — | — | 43.6 | +9.2% |
| Nkarta | $2.80 | +1.45% | $197.5M | — | — | — | — |
| Median | 31.5 | 27.8 | 96.9 | +12.5% |